Cilostazol and outcome in outpatients with peripheral artery disease

Thrombosis Research

Volumn 134, Issue 2, 2014, Pages 331-335

  Perez, Paulina ^a   Esteban, Carlos ^a   Sauquillo, Joan Carles ^b   Yeste, Monserrat ^c   Manzano, Luis ^d   Mujal, Abel ^e   Jiménez Caballero, Pedro Enrique ^f   Aguilar, Eduardo ^g   Sánchez Muñoz Torrero, Juan Francisco ^f   Monreal, Manuel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Hospital Municipal de Badalona   (Spain)

^c HOSPITAL DE TERRASSA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e Hospital Universitari Parc Tauli (Sabadell)   (Spain)

^f HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^g Hospital de Alcañiz Alcañiz   (Spain)

Author keywords

Cilostazol; Intermittent claudication; Outcome; Safety

Indexed keywords

CHOLESTEROL; CILOSTAZOL; CREATININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; FIBRINOLYTIC AGENT; PHOSPHODIESTERASE III INHIBITOR; TETRAZOLE DERIVATIVE;

AGED; ANEURYSM RUPTURE; ARTICLE; BLEEDING; BODY MASS; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISSEMINATED CANCER; DRUG USE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; INTERMITTENT CLAUDICATION; LIMB AMPUTATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MESENTERIC ISCHEMIA; MORTALITY; NEOPLASM; OUTPATIENT; PRIORITY JOURNAL; SMOKING; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; REGISTER; TREATMENT OUTCOME;

AGED; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTPATIENTS; PERIPHERAL ARTERIAL DISEASE; PHOSPHODIESTERASE 3 INHIBITORS; REGISTRIES; STROKE; TETRAZOLES; TREATMENT OUTCOME;

EID: 84905124279     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.05.040     Document Type: Article

References (20)

1. K. Schor The pharmacology of cilostazol Diabetes Obes Metab 4 Suppl. 2 2002 S14 S19
2. L. Pearce, J. Ghosh, A. Counsell, and F. Serracino-Inglott Cilostazol and peripheral arterial disease J Stroke Cerebrovasc Dis 17 2008 129 133
3. R.L. Pande, W.R. Hiatt, P. Zhang, N. Hittel, and M.A. Creager A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intemittent claudication Vasc Med 15 2010 181 188
4. M.E. O'Donnell, S.A. Badger, M.A. Sharif, I.S. Young, B. Lee, and C.V. Soong The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease J Vasc Surg 49 2009 1226 1234
5. A.H. Momsen, M.B. Jensen, C.B. Norager, M.R. Madsen, T. Vestersgaard-Anderesen, and J.S. Lindholt Drug therapy for imporving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies Eur J Vasc Endovasc Surg 38 2009 463 474
6. P.D. Thompson, R. Zimet, W.P. Forbes, and P. Zhang Meta-Analysis of results form eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication Am J Cardiol 90 2002 1314 1319
7. R. Barba, J. Bisbe, J.N. Pedrajas, J. Toril, R. Monte, and J.F. Muñoz-Torrero et al. Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: Findings from the FRENA registry Eur J Cardiovasc Prev Rehabil 16 2009 457 463
8. L.R. Alvarez, J.M. Balibrea, J.M. Suriñach, R. Coll, M.T. Pascual, and J. Toril et al. Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular, or peripheral artery disease Eur J Prev Cardiol 20 2013 486 495
9. J.M. Suriñach, L.R. Alvarez, R. Coll, J.A. Carmona, C. Sanclemente, and E. Aguilar et al. Differences in cardiovascular mortality in smokers, past-smokers and non-smokers: findings from FRENA registry Eur J Intern Med 20 2009 522 526
10. A.M. Garcia-Diaz, P.J. Marchena, J. Toril, G. Arnedo, J.F. Muñoz-Torrero, and M. Yeste et al. Alcohol consumption and outcome in stable outpatients with peripheral artery disease J Vasc Surg 54 2011 1081 1087
11. E. Aguilar, A.M. García-Díaz, J.F. Sánchez Muñoz-Torrero, L.R. Alvarez, M. Piedecausa, and G. Arnedo et al. Clinical outcome of stable outpatients with coronary, cerebrovascular or peripheral artery disease, and atrial fibrillation Thromb Res 130 2012 390 395
12. J.A. Dormandy, and R.B. Rutherford Management of peripheral arterial disease (PAD). TASC Working group. TransAtlantic Inter-Society Consensus (TASC) J Vasc Surg 31 2000 S1 S296
13. L. Pasqualini, G. Schillaci, G. Vaudo, S. Innocente, G. Ciuffetti, and E. Mannarino Predictors of overall and cardiovascular mortality in peripheral arterial disease Am J Cardiol 88 2001 1057 1060
14. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
15. D.O. Martin, and H. Austin Exact estimates for a rate ratio Epidemiology 7 1996 29 33
16. L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, and F.G. Fowkes TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) J Vasc Surg 45 Suppl. S 2007 S5 S67
17. P. Alonso-Coello, S. Bellmunt, C. McGorrian, S.S. Anand, R. Guzman, and M.H. Criqui et al. Antithrombotic therapy in peripheral artery disease. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelaines Chest 141 2 Suppl 2012 e669S e690S
18. C.M. Pratt Analysis of the Cilostazol Safety Database Am J Cardiol 87 2001 28D 33D
19. U. Tamhane, P. Meier, S. Chetcuti, K.Y. Chen, S.W. Rha, and M.P. Grossman et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials Eurointervention 5 2009 384 393
20. European Medicines Agency recommends restricting use of cilostazol-containing medicines EMA/98571/2013.